胰腺癌恶性程度高，预后差，严重危害人类的健康。早期、准确诊断是提高生存率的关键。基于MUC5AC在正常胰腺组织及胰腺炎中低表达，在胰腺早期瘤变PanINs各期及胰腺癌中高表达，我们选择MUC5AC为成像靶点，首先构建具有荧光和磁性纳米MR成像的双模式靶向探针，采用Elisa法、电子衍射、zeta电位、振动磁强计等方法， 对该探针进行性能检测； 其次，将该探针和胰腺癌细胞BxPC3进行系列体外实验，并和正常胰岛细胞对照；然后，将靶向探针注入胰腺癌和胰腺炎小鼠动物模型体内，进行靶向活体MR分子水平显像；最后，取该两种小鼠动物病变和周围组织标本，应用免疫组化、逆转录-聚合酶链反应、Western 印迹法等进行常规病理和免疫组化检测，并与两种动物模型的靶向增强结果进行对照分析。其研究目的就是基于MUC5AC靶向分子成像，活体、动态评价胰腺癌，希望实现对胰腺癌在分子水平早期特异性诊断之目的。

Pancreatic cancer is highly malignant and the prognosis is poor, and does great harm to human health. Early, accurate diagnosis is the key to the improvement of survival rate of the patients. Based on the low expression of MUC5AC in the normal pancreatic tissue and pancreatitis, high expression in PanINs and pancreatic cancer, we choose MUC5AC for imaging targets. Firstly, we established dual-mode targeted probe with fluorescent and magnetic Nano-MR imaging (Cy5.5-anti-MUC5AC-MNPs). The qualities and functions of the probe were tested by Elisa method, electronic diffraction, zeta potential, vibration magnetometer. Secondly, a series of experiments in vitro were performed with molecular probe and pancreatic cancer cells BxPC3, as well as in normal islet cells for comparison. Thirdly, targeted molecular contrasts were injected into animal models of pancreatic cancer and pancreatitis. Targeted MR molecular imaging was done in vivo. Finally, the two murine lesions and surrounding tissue specimens were tested by immunohistochemistry, reverse transcription-polymerase chain reaction (RT-PCR), Western blotting and routine pathological and immunohistochemical methods, and the results of targeted enhancement in animal models of pancreatic cancer and pancreatitis were compared. Based on the MUC5AC targeted molecular imaging in vivo, dynamic evaluation of pancreatic cancer, the research aims to achieve early and specific diagnosis at the molecular level in pancreatic cancer.